BenzingaDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 18:55:38·⟳ 抓取 18:59:30 +3m52s·⚡ 决策 10-16 19:01:39 +2m09s·11.1 天前
Omeros 的 narsoplimab(YARTEMLEA) 欧洲上市申请复审仍遭 CHMP 负面意见，公司终止欧洲同情用药计划
这是6月首次CHMP负面意见的复审维持，属预期内确认；欧洲尚无收入、原计划第三方授权，核心价值来自美国快速放量，盘前仅跌约2.6%且较早盘低点明显收回，市场已按低materiality定价。做空缺乏新增、重大、未预期的催化，做多又面对监管利空，故不做。
📄 原文Benzinga↗ 原文
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicine…
不做 Omeros Corporation（OMER.US）
利空为6月首次CHMP负面意见的复审维持、属预期内确认；欧洲无现实收入且原计划第三方授权，核心估值锚在美股放量(Q2毛收入3220万美元、环比+190%，NTAP生效)，盘前仅跌约2.6%并自低点收回，做空缺少新增重大未预期催化、做多又面对监管利空，风险收益不支持入场。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CHMP复审维持narsoplikumab负面意见并导致欧洲同情用药终止，但这是6月利空的预期内落地，欧洲从未贡献收入、公司估值锚在美股放量；盘前仅小幅下挫并收复大部分失地，无正期望方向，回避。
消息传播链
- 公司2026-10-16发布通稿，确认CHMP复审维持负面意见，并宣布终止欧洲同情用药计划
- EMA 10月12-15日CHMP会议纪要列示Yartemlea复审结果为负面意见，待欧委会决定
- Benzinga报道时OMER盘前跌2.61%至18.30美元市场反应:盘前低见16.99美元后回升至约18.30美元，跌幅收窄至约2.6%
关键理由
- 复审维持负面意见基本符合市场预期(首次负面意见6月已出)，欧洲商业化原本计划授权第三方、无现实收入，增量净损害有限
- 美国基本面向好(Q2 YARTEMLEA毛收入3220万美元、环比+190%，NTAP 10月生效)，盘前跌幅浅且自低点16.99美元收回，印证利空不具持续做空动能
主要风险
- 若投资者将其解读为欧洲选项彻底关闭并下修全球TAM，常规时段可能放大跌幅，但这更偏估值重定价而非新增基本面崩塌
- 公司对复审程序公正性提出异议，后续或有申诉/舆论动作，且美国放量与新适应症进展可能带来双向波动
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-12 · 影响 weakens
美国业务高增长(Q2毛收入3220万美元、环比+190%)且NTAP 10月1日生效，构成对做空的实质对冲，削弱持续看空逻辑
检索:Omeros YARTEMLEA Q2 2026 revenue 32.2 million Medicare NTAP October 1 launch adoption 原文 ↗ - 做空前查反向 · 来源 quote · 日期 2026-10-16 · 影响 weakens
盘前仅跌约2.6%且自低点16.99美元大幅收回，买卖盘偏弱但未现恐慌，市场将其视为低materiality预期内事件
检索:OMER pre-market reaction October 16 CHMP negative re-examination 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加利空属预期内确认、欧洲无收入，直接支持AVOID而非开空
方向:未取得锚点干净、同市场同机制(CHMP复审维持拒批)且首发时刻可核验的足量先例，不用先例数字定方向或幅度
涨幅量级:无高相似对齐先例，不定tp/sl；本次盘前市场反应(-2.6%且自低点收回)本身已提示低materiality
形态:检索到的多为EMA历史拒批/撤案静态页面(如Glybera复审拒批、Anavex撤案)，无法锚定可交易首发时刻与个股日线，不纳入量化
工具执行结果 · 成功 4 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`omer ema narsoplimab marketing application rejected compassionate use ends | omeros narsoplimab chmp negative opinion re-examination ta-tma`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续 - stock_quote 成功 stock_tools HTTP · 737 ms
{ - web_search 成功 doubao_search · 1,552 ms
豆包搜索结果（原始查询:Omeros OMER narsoplimab CHMP negative opinion re-examination June 2026 analysts EU approval expectations；API SearchType:web） - kb_search 失败 stock_tools HTTP · 58 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 1,738 ms
豆包搜索结果（原始查询:CHMP re-examination upholds negative opinion biotech stock reaction expected approval denied Europe；API SearchType:web）
原文全文
展开原文 · 3,018 字
Omeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicines Agency’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion from June.
- Omeros stock is feeling bearish pressure. Why are OMER shares down?
EMA Panel Upholds Its Negative Opinion on Narsoplimab After Re-Examination
CHMP convened an eight-member ad hoc expert group of hematologists, statisticians and transplant physicians, plus two patient representatives, as part of the re-examination. Omeros said the group answered a single, three-part question prepared by CHMP, and that CHMP’s minutes state the group recommended review of individual patient-level data by external experts. Omeros had submitted substantial patient-level data in August as part of its grounds for re-examination, but said CHMP did not provide that data to the group.
"We are deeply disappointed in the re-examination process and outcome," said Gregory A. Demopulos, Omeros’ chairman and CEO. He said the YARTEMLEA data, the FDA’s broad approval, a decade of compassionate-use requests from European physicians and rapid U.S. adoption point to a favorable benefit-risk profile. There is no approved TA-TMA therapy in Europe.
Omeros Ends Its Compassionate-Use Program and Turns to Named-Patient Access
Omeros said that, because of rising U.S. demand for YARTEMLEA, it has told CHMP it plans to end its compassionate-use program. Patients currently receiving the drug through the program will get enough to complete their treatment courses. The company said it is working to enable fully reimbursed, named-patient access in Europe and other regions where permitted. Omeros had planned to license EU commercialization rights to a third party if the EU granted authorization.
The U.S. Launch Remains Omeros’ Focus
The FDA approved YARTEMLEA in December 2025 for TA-TMA patients two years of age and older. Omeros says it is the first and only approved TA-TMA therapy and the only systemic complement inhibitor on the market without a boxed warning, REMS or vaccination requirement. Omeros reported second-quarter YARTEMLEA gross revenue of $32.2 million, up 190% from the first quarter, and Medicare’s New Technology Add-on Payment for the drug took effect October 1. Omeros plans to begin clinical studies in acute respiratory distress syndrome and in prevention of high-risk TA-TMA in pediatric patients later this year.
Omeros Stock Falls
OMER Price Action: At the time of publication, Omeros shares are trading 2.61% lower at $18.30, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
- Omeros stock is feeling bearish pressure. Why are OMER shares down?
EMA Panel Upholds Its Negative Opinion on Narsoplimab After Re-Examination
CHMP convened an eight-member ad hoc expert group of hematologists, statisticians and transplant physicians, plus two patient representatives, as part of the re-examination. Omeros said the group answered a single, three-part question prepared by CHMP, and that CHMP’s minutes state the group recommended review of individual patient-level data by external experts. Omeros had submitted substantial patient-level data in August as part of its grounds for re-examination, but said CHMP did not provide that data to the group.
"We are deeply disappointed in the re-examination process and outcome," said Gregory A. Demopulos, Omeros’ chairman and CEO. He said the YARTEMLEA data, the FDA’s broad approval, a decade of compassionate-use requests from European physicians and rapid U.S. adoption point to a favorable benefit-risk profile. There is no approved TA-TMA therapy in Europe.
Omeros Ends Its Compassionate-Use Program and Turns to Named-Patient Access
Omeros said that, because of rising U.S. demand for YARTEMLEA, it has told CHMP it plans to end its compassionate-use program. Patients currently receiving the drug through the program will get enough to complete their treatment courses. The company said it is working to enable fully reimbursed, named-patient access in Europe and other regions where permitted. Omeros had planned to license EU commercialization rights to a third party if the EU granted authorization.
The U.S. Launch Remains Omeros’ Focus
The FDA approved YARTEMLEA in December 2025 for TA-TMA patients two years of age and older. Omeros says it is the first and only approved TA-TMA therapy and the only systemic complement inhibitor on the market without a boxed warning, REMS or vaccination requirement. Omeros reported second-quarter YARTEMLEA gross revenue of $32.2 million, up 190% from the first quarter, and Medicare’s New Technology Add-on Payment for the drug took effect October 1. Omeros plans to begin clinical studies in acute respiratory distress syndrome and in prevention of high-risk TA-TMA in pediatric patients later this year.
Omeros Stock Falls
OMER Price Action: At the time of publication, Omeros shares are trading 2.61% lower at $18.30, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
e1b1251dbb· 2026-10-16 19:01 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前